Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial

HIV Clinical Trials

Volumn 14, Issue 1, 2013, Pages 45-50

  Geretti, Anna ^a   Arribas, Jose ^b   Lathouwers, Erkki ^c   Foster, Geraldine ^a   Yakoob, Rabia ^d   Kinloch, Sabine ^e   Hill, Andrew ^f   Van Delft, Yvon ^g   Moecklinghoff, Christiane ^h  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f MetaVirology Ltd   (United Kingdom)

^g Janssen EMEA   (Netherlands)

^h Janssen EMEA   (Germany)

Author keywords

darunavir r monotherapy; HIV 1 DNA; HIV 1 RNA; protease inhibitor

Indexed keywords

DARUNAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

ADULT; AGED; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873382351     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1401-45     Document Type: Article

References (17)

1. Rouzioux C, Hubert J, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ cell counts. J Infect Dis. 2005;192:46-55 (Pubitemid 40863856)
2. Maldarelli F, Palmer S, King M, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viraemia. PLoS Pathogens. 2007;3:484-488 (Pubitemid 46683483)
3. Viard J, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18:45-49 (Pubitemid 38402316)
4. Doyle T, Geretti AM. Low-level viraemia on HAART: signifi - cance and management. Curr Opin Infect Dis. 2012;25:17-25
5. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009;5:e1000533
6. Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol. 2010; 82:1819-1828
7. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13:398-405
8. Katlama C, Valantin MA, Algarte-Genin M, et al. Effi cacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010;24:2365-2374
9. Guaraldi G, Zona S, Cossarizza A, et al. Impact of switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH randomized controlled trial. In: Program and abstracts of the European AIDS Conference; October 2011; Belgrade, Serbia. Abstract PE7.5/4
10. Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR realtime PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol. 2009;81:217-223
11. Avettand-Fenoel V, Flandre P, Chaix M, et al. Impact of 48 week lopinavir/ritonavir monotherapy on blood cellassociated HIV-1-DNA in the MONARK trial. J Antimicrob Chemother. 2010;65:1005-1007
12. Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol. 2012;53: 29-32
13. Marcelin A, Lambert-Niclot S, Peytavin G, et al. Baseline HIV RNA ultrasensitive assay and viral DNA predict rise in plasma viral load in patients of MONOI-ANRS 136 trial. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, Massachusetts. Abstract 533
14. Lambert-Niclot S, Flandre P, Valantin M-A, et al. Similar evolution of cellular HIV-1 DNA level in rarunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS ONE. 2012;7: e41390
15. Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Ther. 2009;14:195-201
16. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204:135-138
17. UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy C PIVOT trial. http://www.controlled- trials.com/ISRCTN04857074. Accessed May 13, 2011.